Effects of a Fixed Combination of Atorvastatin and Fenofibrate on LDL and Non-HDL Cholesterol Levels in Patients with Mixed Dyslipidemia

Read full text Summarise with VIRAT
Authors: Seydi Vanesa Mejía Ruiz, Ginner Odorico Rizo Rivera, Carlos A. Narváez
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study aims to evaluate the effects of a fixed-dose combination of atorvastatin 20 mg and fenofibrate 160 mg (Vaxtifen) on LDL and non-HDL cholesterol levels in adult patients with mixed dyslipidemia. A quasi-experimental, pre-post intervention design without a control group will be used. The study will be conducted over 12 weeks in two cardiometabolic outpatient clinics in Nicaragua, and all participants will receive daily treatment with Vaxtifen. The primary outcomes are the changes in LDL and non-HDL cholesterol levels from baseline to week 12, assessed according to the 2019 ESC/EAS Guidelines. Secondary outcomes include the proportion of patients reaching therapeutic targets based on cardiovascular risk categories and the frequency of adverse events. This research addresses a gap in evidence related to combination lipid-lowering therapy in Latin American populations and aims to contribute to more individualized and effective dyslipidemia management strategies in real-world ambulatory settings.

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Cholesterol and Lipid Metabolism Diabetes Cardiovascular Risks and Lipoproteins

Publication details

Journal / source
OSF Preprints (OSF Preprints)
Publication date
16 March 2026
Language
EN
Document type
Preprint